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Abstract
We report a case of phacoemulsification conversion complicated by suprachoroidal haemorrhage (SCH) and
delayed rebleeding at day 5 postoperation, as the first presentation of bullous pemphigoid associated acquired
hemophilia. This association has been reported sparingly in the past, and almost exclusively only in hematology
literature. To the best of our knowledge, this is the first case of delayed SCH rebleed presenting in a patient with
previously undiagnosed Acquired Hemophilia reported. Although exceedingly rare, acquired hemophilia leads to
drastic complications and has a high mortality rate. Advice to allow early recognition and prevention of complications
is summarized.
Keywords: Suprachoroidal haemorrhage; Delayed rebleed; Acquired
haemophilia; Phacoemulsification complication; Bullous pemphigoid
association
Introduction
Suprachoroidal hemorrhage (SCH) is a rare but devastating
complication of cataract surgery. We report a case of
phacoemulsification conversion complicated by SCH and delayed
rebleeding, as the first presentation of previously undiagnosed bullous
pemphigoid associated acquired hemophilia. This association has been
reported sparingly in the past, and almost exclusively only in
hematology literature. To the best of our knowledge, this is the first
case of delayed SCH rebleed presenting in a patient with previously
undiagnosed Acquired Hemophilia reported.
Case Presentation
A 66-year-old Chinese man was electively admitted for
phacoemulsification surgery and intraocular lens (IOL) insertion of
the left eye. For past medical history, the patient suffered from bullous
pemphigoid with mucosal involvement, hypertension, hyperlipidemia,
and recurrent metachronous colorectal cancer with multiple
resections. The patient has borderline renal function. He was not on
any anticoagulants and there was no reported history of coagulation
disorder.
He has known high myopia with a long axial length of 30.63mm in
the operating eye (Axial length biometry A-Scan, Eyecubed™, Ellex).
Autorefraction was -19.25 over the right eye and the machine failed to
obtain a reading in the left eye. His pre-operative best-corrected visual
acuity (BCVA) was 20/100 in both eyes. Slit lamp examination revealed
dense nuclear sclerosis of grade IV in both eyes.
A peri-bulbar block was performed with an injection of 2%
lignocaine mixed with hyaluronidase before the start of surgery.
Paracentesis and a 2.75 mm superior corneal wound were made,
followed by continuous curvilinear capsulorhexis (CCC), which was
halted by a run-away at 5 o’clock position. The operation was converted
to extracapsular cataract extraction. After removal of the anterior
capsule, relaxing incisions were made at the superior CCC rim.
Corneal wound extension, nucleus expression and cortex removal with
irrigation and aspiration were completed uneventfully. The lens
capsule was inflated with viscoelastic, and the anterior capsular rim
could still be visualized.
An EZE60 IOL (Bausch & Lomb) was inserted, which was
complicated by a posterior capsular rupture (PCR). Loss of vitreous
was noted and the IOL was removed. At this point, the patient
complained of urinary urgency, followed by severe ocular pain. Loss of
red reflex was noted, with further anterior displacement of vitreous
and mild iris prolapse. With the suspicion of suprachoroidal
hemorrhage (SCH) in mind, viscoelastic was injected to arrest further
protrusion of intraocular contents, followed by immediate wound
closure with 10–O nylon sutures. The anterior chamber (AC) was well
formed after successful wound closure. Limited anterior vitrectomy
was performed and no vitreous or retinal incarceration in wound was
noted at the end of operation. Intra-cameral Zinacef was injected at the
end of the operation and IOP was maintained at around mid-20
mmHg. On binocular indirect ophthalmoscopy immediately post-
operation, there was loss of red reflex and a superior ciliary body bulge
was seen behind iris.
On postoperative day, visual acuity of the left eye was hand motion
only and the left eye intraocular pressure (IOP) was 19. Slit lamp
examination showed stable wounds with negative Seidel test,
significant injection with chemosis, corneal edema, descemet
membrane folds, a well formed anterior chamber with vitreous at the
pupillary plane and a superior ciliary body bulge behind the superior
pupil plane.
B-scan (Figure 1) confirmed superior and inferior suprachoroidal
hemorrhage without significant central choroidal apposition. Post-
operative treatment included: 1% Prednisolone Forte (prednisolone
acetate ophthalmic suspension, USP) and 0.5% Cravit (Levofloxacin)
eye drops given hourly during daytime; 10 mg of oral prednisolone;
and maximal anti-glaucoma medications including oral acetazolamide
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250 mg twice daily, topical 0.5% timolol, 0.1% alphagan-P
(Brimonidine Tartrate) and 1% azopt (brinzolamide ophthalmic
suspension). The intraocular pressure was kept within mid to late teens
over the first 4 days.
Figure 1: B-scan: Suprachoroidal haemorrhage.
On postoperative day 5, the patient did not complain of any pain
but the intraocular pressure suddenly increased to 43 mmHg. Left eye
reverse relative afferent pupillary defect was positive. There was
increase in chemosis. The wounds remained stable but the anterior
chamber became shallow. A repeat B-scan showed an increase in size
of SCH, now with kissing choroidal.
In view of the rarity of a rebleed on postoperative day 5 in the
context of stable wounds, the patient was asked about history of
bleeding tendencies. The patient revealed that he suffered from a
spontaneous lip hematoma 6 months prior to this admission, and had
been experiencing significant bruising after routine blood tests over
the same time period. Blood tests for complete blood count and
clotting were taken. Immediately after venesection, the patient
developed continuous oozing from the puncture site, which required
prolonged pressure compression, and ultimately resulted in extensive
swelling over the left anterior cubital fossa (Figure 2).
Figure 2: Hematoma of left anterior cubital fossa, after blood taking.
Blood tests revealed a hemoglobin level of 7.8 g/dL (normal range
13.8-18.0), prolonged activated partial thromboplastin time (APTT) of
64 seconds (normal range: 23-35 seconds), with a normal Prothrombin
time (PT) of 12.9 (normal range: 9.5-13.5) and a normal International
normalized ratio of 1.1 (normal range 0.8-1.2). These results were
suggestive of an acquired coagulation disorder.
Urgent referral to the hematologist and further blood tests were
done to establish a definitive diagnosis. The Factor VIII level of the
patient was <0.01 IU/ml (reference range: 0.5-1.75 IU/ml), Factor VIII
inhibitor was 57.3 Bethesda Unit (normal range: <10), which lead to
the diagnosis of Acquired Hemophilia.
He was treated with 5 mg of NovoSeven (recombinant human
coagulation Factor VIIa) injections pro re nata during acute bleeding
episodes post-venesection. A total of 15 NovoSeven injections were
given over the course of his admission. Four units of blood
transfusions were given to normalize hemoglobin levels. Oral
prednisolone 60 mg and Cyclophosphamide 50 mg daily were initiated.
The APTT remained high but showed a decreasing trend, reducing to
46.7 after one week of treatment.
His chemosis resolved quickly after commencement of oral steroids
and NovoSeven (Figure 3), and the IOP gradually returned to normal.
At 16 days postoperation, the patient was noted to develop early band
keratopathy. At postoperation day 12, the visual acuity was reduced to
no light perception (NLP). In view of poor visual prognosis and
significant bleeding risk, surgical drainage was not recommended.
Figure 3: Postoperative day 12-Chemosis resolved.
Discussion
Acquired hemophilia (AH) is an exceedingly rare condition, with an
incidence of approximately 1.5 persons per million each year [1] and a
mortality rate of 9-22% [2]. The condition is caused by spontaneous
development of inhibitory autoantibodies against endogenous
coagulation factors in individuals with no previous history of bleeding
disorders [2]. All coagulation factors have been implicated, with the
most commonly affected one being Factor VIII [3,4]. Approximately
50% of cases are idiopathic; 12-18% is associated with autoimmune
diseases-the most common ones being systemic lupus erythematosus,
rheumatoid arthritis and Sjögren’s syndrome [5-8]. The rest of AH
cases are associated with malignancies, pregnancy, infections, adverse
drug reactions and dermatological conditions. According to our
literature review, only 17 documented cases of bullous pemphigoid
(BP) associated AH have been reported hitherto. Presenting symptoms
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of BP associated AH include hematomas, ecchymosis, gastrointestinal
bleeding and oral mucosal bleeding. This was compatible with the
history of lip hematoma in our patient [9-19].
To the best of our knowledge, there has been no previous report of
SCH in patients suffering from AH, although there was one case report
of uncontrolled bleeding following eyelid tumor resection in a patient
with previously undiagnosed AH [20]. A few cases of ocular bleeding
associated with Congenital Hemophilia have been reported, with
delayed bleeding as a recurrent feature [21-24]. Delayed, uncontrolled
or otherwise suspicious bleeding should raise the suspicion of
coagulopathies.
The goal of treatment in AH is twofold: to achieve hemostasis in
acute bleeding episodes, and to eradicate coagulation inhibitors to
prevent life-threatening haemorrhage [25,26]. In our case,
recombinant Factor VIIa (NovoSeven) was used to achieve temporary
hemostasis. It was effective, albeit short-acting, in controlling the
continuous oozing from needle puncture sites. To achieve complete
remission of AH, data from the European Acquired Hemophilia
Registry has shown that the combination of Cyclophosphamide and
steroids is the most effective regime, compared with steroids alone or
steroids with Rituximab [27].
SCH can be classified into postoperative and spontaneous. The
incidence of SCH complicating phacoemulsification and ECCE is
0.03% and 0.13% respectively [28,29]. Risk factors for postoperative
SCH include high myopia, glaucoma, diabetes, hypertension and
atherosclerosis. Intraoperative risk factors include PCR (52.3% of SCH
cases), ECCE, and phacoemulsification conversion [30]. A study
auditing 55,567 cataract operations concluded that anti-coagulant use
was not associated with an increased risk [31]. The risk factors for
spontaneous SCH are almost identical to postoperative SCH, with the
exception of anti-coagulant use. A meta-analysis showed that
abnormal coagulopathy and the use of anti-coagulants were both
major risk factors in spontaneous SCH in patients aged over 60,
associated with 82.6% and 69.6% of the cases respectively [32]. With
regards to use of warfarin, spontaneous SCH can occur when the INR
is within or over therapeutic range [33,34].
Management of SCH is controversial, with different sources of
evidence-based arguments supporting both conservative and surgical
treatment) [35,36]. Intraoperative steps taken to manage SCH include
from wound closure alone, intravenous mannitol, intravenous Diamox,
anterior vitrectomy and trans-scleral drainage of suprachoroidal blood
[37]. There is, however, a general consensus that immediate drainage of
SCH is difficult and potentially detrimental [38,39]. One large case
series of patients with SCH showed that there is no statistically
significant difference in visual outcome between conservative and
surgical management [40]. In contrast, a more recent case report of 4
patients with massive SCH who underwent surgical intervention
showed promising results [41]. The procedure entailed trans-scleral
suprachoroidal drainage, pars plana vitrectomy, use of perfluorocarbon
liquid to displace the hemorrhage from the posterior pole and silicone
oil tamponade. All 4 patients had a pre-operative visual acuity of light
perception, but had variable postoperative visual acuity of 20/20,
20/320, hand motion and no light perception.
Poorer visual outcome has been shown to be significantly correlated
with the severity of SCH. Features associated with poorer outcomes
include central retinal apposition, and vitreous or retinal incarceration
in the wound [42]. Our patient developed central retinal opposition
after SCH rebleed on postoperation day 5. This feature has generally
been regarded as a relative indication for surgical intervention, [40,43]
although one case report has shown visual acuity improvement from
hand motion to 20/50 by conservative management alone [44].
The mean SCH clot lysis time has been shown to be around 2 weeks
via ultrasonography, and thus, the traditional school of thought is to
delay drainage by 1 to 2 weeks [36,45-47]. Multiple reports have
observed that the time interval for intervention should not exceed two
weeks [38,40,41]. During the optimum surgical window of 7 to 14
days, our patient had prolonged APTT and continued to suffer from
uncontrolled bleeding from simple venesection. In view of this
increased risk of bleeding and poor visual potential, secondary
drainage was not pursued. Unfortunately, our patient had central
retinal opposition which persisted for over 2 weeks postoperatively,
with no signs of clot lysis on ultrasonography. This is generally
associated with dismal visual outcome, regardless of the type of
management [40].
Whilst it is not practical to perform blood tests on every patient
undergoing cataract surgery to screen for rare bleeding disorders such
as AH, this case highlights the importance of further history taking in
those who are at high risk for developing SCH, e.g. to ask about history
of spontaneous bleeding, easy bruising or prolonged bleeding episodes.
Patients with any suspicion of a bleeding disorder should then be
further worked up with clotting blood tests. Cases of SCH with delayed
postoperative rebleeding should raise suspicion of a bleeding disorder,
especially if there is no history of anticoagulant use. Urgent
coagulation blood tests and timely referral to a hematologist could
prevent life-threatening hemorrhagic death in those with acquired
hemophilia.
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